Board of Directors
Ms. Petrovic has served as our President and Chief Executive Officer since January 1, 2019 and has served on our Board of Directors since September 2018. She also serves on the Board of Directors of Exact Sciences Corporation. Prior to becoming Chief Executive Officer, she served as Insulet’s President and Chief Operating Officer from October 2016 to December 31, 2018. From February 2016 to October 2016, she served as our Executive Vice President and President, Diabetes Products, and from February 2015 to February 2016, she served as our Chief Commercial Officer. From 2013 to 2015, Ms. Petrovic served as President and Chief Executive Officer of Clinical Innovations, LLC, a developer and manufacturer of medical devices and diagnostics for women’s health. From 2000 to 2013, she served in a number of key roles at Hologic, Inc. and Cytyc Corporation, which merged with Hologic in October 2007, including Vice President and General Manager of Hologic’s GYN Surgical Products division, as well as various sales and marketing leadership roles in the U.S. and Europe. Ms. Petrovic earned her Bachelor of Science in Biology from the University of Wisconsin.
Dr. Borio has served on our Board of Directors since October 2021. She is a venture partner at ARCH Venture Partners where she advises on new investment opportunities related to biologics manufacturing, clinical trials, novel therapies, and areas with large unmet clinical needs. She also serves on the Board of Directors of Eagle Pharmaceuticals, Inc. From 2019 to 2020, she was Senior Vice President at In-Q-Tel, an independent, non-profit, strategic investment firm. From 2017 to 2019, she was Director for Medical and Biodefense Preparedness Policy at the National Security Council. While at the FDA from 2009 to 2017, Dr. Borio held roles of increasing responsibility, including Acting Chief Scientist and Assistant Commissioner for Counterterrorism Policy. She helped develop and execute the FDA’s medical countermeasures and public health responses to the 2009 H1N1 flu pandemic, the 2014 Ebola epidemic, and the 2015 Zika outbreak. She also served on the World Health Organization’s Emergency Preparedness and Response Scientific Advisory Group.
Most recently, Dr. Borio served as a member of the President’s Transition COVID-19 Advisory Board. Dr. Borio is a practicing physician at Johns Hopkins Hospital and a senior fellow for Global Health at the Council on Foreign Relations. She earned a Doctor of Medicine from George Washington University School of Medicine and a Bachelor of Science in Zoology from George Washington University.
Ms. Crawford has served on our Board of Directors since 2008 and served as our Lead Independent Director from May 2009 to May 2013. She served as Chief Operating Officer of Healthsource, Inc., a publicly-held managed care organization from its founding in 1985 until 1997. During her tenure at Healthsource, she led the development of its operating systems and marketing strategies and supported strategic alliances with physicians, hospitals, insurers and other healthcare companies. Since 1997, Ms. Crawford has been a healthcare consultant. She serves on the Board of Directors of Hologic, Inc. and Prolacta Bioscience Inc. and Abcam plc. She also served on the Board of Directors of Exact Sciences Corporation from 1999 to 2015, Zalicus Inc. from 2007 to 2014, Universal American from 2008 to 2017, Chittenden Corporation from 1998 to 2008, and Cytyc Corporation (which merged with Hologic, Inc. in October 2007) from 1998 to 2007. Ms. Crawford earned a Bachelor of Arts from Smith College and a Master of Science from Boston University. She brings experience as a board and committee member of public companies, a detailed understanding of the healthcare and managed care industries, which are directly relevant to our business, and the practical knowledge gained in her previous role as chief operating officer of a publicly-held managed care organization.
Dr. Frederick has served on our Board of Directors since October 2020. He is the president of Howard University and serves as the Charles R. Drew Endowed Chair of Surgery at Howard University’s College of Medicine. Prior to being appointed president in 2014, Dr. Frederick served as Howard University’s Provost and Chief Academic Officer.
Dr. Frederick is a practicing surgeon, distinguished researcher and scholar, and the author of numerous peer-reviewed articles, book chapters, abstracts, and editorials. He has received several awards for his scholarship and public service and continues lectures to medical students and residents of Howard’s College of Medicine. He is a fellow of the American College of Surgeons and belongs to numerous surgical organizations, including the American Surgical Association.
As a widely recognized expert on disparities in healthcare and medical education, his medical research focuses on narrowing racial, ethnic, and gender disparities in cancer care outcomes among African Americans and other underrepresented groups. Dr. Frederick has served as the principal investigator for major collaborations with the National Cancer Institute and Johns Hopkins University, as well as several national minority-serving oncology programs.
He received his Bachelor of Science, Doctor of Medicine, and Master of Business Administration from Howard University. Dr. Frederick also serves on the Board of Directors of Humana Inc., Forma Therapeutics Holdings, Inc., Mutual of America Life Insurance Co. and Tempus Labs, Inc., as well as other privately held companies and charitable organizations. Dr. Frederick’s vast experience in medical research, healthcare academics, and business administration brings valuable insights to Insulet’s Board.
Dr. Hollingshead has served on our Board of Directors since July 2019. He currently serves as President of the Sleep and Respiratory Care business at ResMed Inc., a publicly-held global medical technology company focused on the treatment of sleep-related breathing disorders. As President of ResMed’s SRC business, Dr. Hollingshead led ResMed’s transformation from a traditional medical hardware technology business to a SaaS-based digital solutions and services business. From 2011 to 2017, he held numerous positions at ResMed, including President, Americas, Chief Strategy Officer, and President, Ventures & Initiatives. Previously, Dr. Hollingshead spent nearly two decades in strategy consulting across a range of industries including biotech, high-tech, and telecommunications. He serves on the Board of SleepScore Labs, a privately-held joint venture between ResMed, Pegasus Capital and Oz Media. Prior, he was a senior partner in the Strategy and Life Sciences practices at Deloitte Consulting and also served as Managing Partner at Monitor Group, a U.S. strategy consulting firm, including serving in various global roles, including Founder and Managing Partner and European Marketing Strategy Practice in the U.K. and Office Managing Partner in Istanbul. Dr. Hollingshead holds a Bachelor of Arts in History and International Relations with Highest Distinction from Stanford University, and a Master’s Degree and Ph.D. in Political Science from the University of California, Berkeley, where he was awarded a graduate student Fellowship by the National Science Foundation. He brings to the Insulet Board a unique combination of digital strategy and transformation expertise, as well as global corporate leadership and consulting experience in the biotech and life sciences sectors.
Dr. Hopfield, who is NACD Directorship certified, has served on our Board of Directors since July 2015 and served as our Lead Independent Director from August 2016 to January 2019. Dr. Hopfield is a current Trustee and former Chair of the Joslin Diabetes Center. She also serves on the Boards of Directors of Editas Medicine and Maravai. Dr. Hopfield is a distinguished healthcare executive and diabetes expert with over two decades of experience in the medical and healthcare fields. She is a strategic advisor and investor in healthcare and technology firms seeking to commercialize innovative intellectual property. From 1995 to 2009, Dr. Hopfield was a Partner of McKinsey & Company in their global pharmaceuticals and medical devices practice and she served clients across pharmaceutical, biotech, medical device and consumer industries with a focus on strategy, R&D management and marketing. Dr. Hopfield also previously held management positions at Merck Sharp & Dohme Corp. in clinical development, outcomes research, and marketing. She earned a Bachelor of Science from Yale College, a Master of Business Administration from Harvard Graduate School of Business Administration as a Baker Scholar, and a Doctor of Philosophy in Neuroscience/Biochemistry from The Rockefeller University. Dr. Hopfield brings proven experience in the diabetes field, along with vast executive and consulting experience in the healthcare, pharmaceutical, and medical device industries.
Mr. Lemoine has served on our Board of Directors since February 2016. From 1985 until his retirement in 2010, Mr. Lemoine held the position of Audit Partner at Deloitte & Touche LLP, a public accounting firm. From 1995 to 2000, he served as Deloitte’s Boston office Audit Partner-in-Charge and from 1985 to 1995, he served as Deloitte’s Managing Partner of their Worcester, Massachusetts location. From 1980 to 1985, Mr. Lemoine was Senior Vice President, Finance and Administration at Briox Technologies, Inc., a medical equipment manufacturer of home healthcare durable medical equipment. Mr. Lemoine was an Adjunct Professor at Boston College’s Carroll School of Management from 2008 to 2014, where he taught courses in Ethics and Accounting. He previously served on the Board of Directors of The L.S. Starrett Company from 2010 through 2020. He earned a Bachelor of Arts in Economics from Boston College and a Master of Science in Accounting from Northeastern University. He is a Certified Public Accountant and a member of the American Institute of Certified Public Accounts and the Massachusetts Society of CPAs. Mr. Lemoine has over 40 years of audit and finance experience and a deep knowledge of accounting, financial reporting and internal controls across a broad array of industries, including manufacturing, biotechnology, pharmaceutical, technology, and healthcare.
Mr. Minogue has served on our Board of Directors since August 2017. He currently serves as Chief Executive Officer, President and Chairman of Abiomed Inc., a global leader in healthcare technology and innovation. He joined Abiomed from GE Healthcare, where he holds three patents and spent 11 years developing expertise in sales, marketing, product development, information technologies and software/service operations. Mr. Minogue currently serves on the Board of Directors of AdvaMed and as Chairman of Medical Device Innovation Consortium, a public-private partnership with the industry, government and nonprofits. Mr. Minogue is also Chairman of the Governor’s Advisory Council on Veterans’ Services for the Commonwealth of Massachusetts. He is also on the Board of Managers for Bioventus LLC and recently stepped down from his position as Chairman after concluding ten years of service on the Board of Directors for MassMEDIC. Mr. Minogue is the Co-Founder and Chairman of the Mentoring Veterans Program (MVPvets), a nonprofit organization that helps military veterans network with industry mentors to discover career opportunities in the life sciences industries. He served as an Infantry officer in the U.S. Army, which included multiple distinctions, including Airborne Ranger, Desert Storm Veteran and he was awarded the Bronze Star. Mr. Minogue received a Bachelor of Science, Engineering Management from the United States Military Academy at West Point and an MBA from the University of Chicago. Mr. Minogue brings distinguished leadership experience, as well as direct experience driving innovation and product development.
Ms. Nevinny has served on our Board of Directors since January 2019. Since 2019, Ms. Nevinny has served as General Partner of Avestria Ventures, a venture capital firm focused on early stage investments in women’s health care and women in Lifesciences. She also serves as General Partner at LMNVC, a seed venture fund making early-round investments in start-up companies that have products or provide services to improve quality of life, including health and wellness oriented businesses. From 2003 to 2010, she served in various roles at Edwards Lifesciences Corporation, including General Manager – Cardiac Surgery Systems, President of Global Operations, and Chief Financial Officer and Treasurer. During this time, Ms. Nevinny was responsible for global manufacturing, quality and supply chain operations, as well as oversight of core operating units including finance, IT, internal audit and risk management. Prior to joining Edwards, Ms. Nevinny held various finance and investment banking positions. Ms. Nevinny is a member of the Board of Trustees and Executive Committee of the United States Olympic and Paralympic Foundation and serves on the Board of Directors of Restorsea LLC. She previously served on the Board of privately-held nVision, as well as public company Boards, including Avanir Pharmaceuticals, Inc., Neurocrine Biosciences, Onyx Pharmaceuticals, Inc., and SangStat Medical Corp. and chaired the Audit Committees for Avanir, Neurocrine and Onyx. Ms. Nevinny brings considerable public board experience and a breadth of first-hand experience managing complex global finance, logistics, regulatory and manufacturing operations, which are directly relevant to our business. Ms. Nevinny holds a Bachelor of Science in Industrial Engineering from Stanford University and a Master of Business Administration from Harvard Business School.
Mr. Scannell has served on our Board of Directors since August 2014 and as our Chairman of the Board since January 1, 2019. He also serves on the Board of Directors of Novocure. Since October 1, 2021, he has served as Advisor to the Chief Executive Officer at Stryker Corporation, one of the world's leading medical technology companies that offers innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes. From August 2018 to September 30, 2021, he served as the President and Chief Operating Officer at Stryker and from 2009 to August 2018, he served as a Group President and oversaw several of Stryker’s operating divisions, including Instruments, Medical, Endoscopy, Neurovascular, CMF, and Sustainability Solutions. From 1990 to 2009, Mr. Scannell served in various roles at Stryker, including a range of sales and marketing leadership roles, Vice President and General Manager of its Biotech division and President of its Spine business. Mr. Scannell holds a Bachelor of Business Administration and a Master of Business Administration from the University of Notre Dame. He brings extensive strategic, organizational, and operational skills and experience.